342 related articles for article (PubMed ID: 28864724)
1. Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity.
Anagnostou V; Yarchoan M; Hansen AR; Wang H; Verde F; Sharon E; Collyar D; Chow LQM; Forde PM
Clin Cancer Res; 2017 Sep; 23(17):4959-4969. PubMed ID: 28864724
[TBL] [Abstract][Full Text] [Related]
2. Challenges and Opportunities in Adapting Clinical Trial Design for Immunotherapies.
Siu LL; Ivy SP; Dixon EL; Gravell AE; Reeves SA; Rosner GL
Clin Cancer Res; 2017 Sep; 23(17):4950-4958. PubMed ID: 28864723
[TBL] [Abstract][Full Text] [Related]
3. The Challenge for Development of Valuable Immuno-oncology Biomarkers.
Mehnert JM; Monjazeb AM; Beerthuijzen JMT; Collyar D; Rubinstein L; Harris LN
Clin Cancer Res; 2017 Sep; 23(17):4970-4979. PubMed ID: 28864725
[TBL] [Abstract][Full Text] [Related]
4. Immuno-oncology Clinical Trial Design: Limitations, Challenges, and Opportunities.
Baik CS; Rubin EH; Forde PM; Mehnert JM; Collyar D; Butler MO; Dixon EL; Chow LQM
Clin Cancer Res; 2017 Sep; 23(17):4992-5002. PubMed ID: 28864727
[TBL] [Abstract][Full Text] [Related]
5. Improved endpoints for cancer immunotherapy trials.
Hoos A; Eggermont AM; Janetzki S; Hodi FS; Ibrahim R; Anderson A; Humphrey R; Blumenstein B; Old L; Wolchok J
J Natl Cancer Inst; 2010 Sep; 102(18):1388-97. PubMed ID: 20826737
[TBL] [Abstract][Full Text] [Related]
6. The changing face of clinical trials in the personalized medicine and immuno-oncology era: report from the international congress on clinical trials in Oncology & Hemato-Oncology (ICTO 2017).
Golan T; Milella M; Ackerstein A; Berger R
J Exp Clin Cancer Res; 2017 Dec; 36(1):192. PubMed ID: 29282151
[TBL] [Abstract][Full Text] [Related]
7. Significance of emerging clinical oncology endpoints in support of overall survival.
Patil S; Agarwal V; Drupad HS
Indian J Cancer; 2022 Mar; 59(Supplement):S106-S118. PubMed ID: 35343195
[TBL] [Abstract][Full Text] [Related]
8. The promise of Immuno-oncology: implications for defining the value of cancer treatment.
Kaufman HL; Atkins MB; Subedi P; Wu J; Chambers J; Joseph Mattingly T; Campbell JD; Allen J; Ferris AE; Schilsky RL; Danielson D; Lichtenfeld JL; House L; Selig WKD
J Immunother Cancer; 2019 May; 7(1):129. PubMed ID: 31101066
[TBL] [Abstract][Full Text] [Related]
9. Impact of pharmacodynamic biomarkers in immuno-oncology phase 1 clinical trials.
Salawu A; Hernando-Calvo A; Chen RY; Araujo DV; Oliva M; Liu ZA; Siu LL
Eur J Cancer; 2022 Sep; 173():167-177. PubMed ID: 35872510
[TBL] [Abstract][Full Text] [Related]
10. End points and statistical considerations in immuno-oncology trials: impact on multiple myeloma.
Hoering A; Durie B; Wang H; Crowley J
Future Oncol; 2017 Jun; 13(13):1181-1193. PubMed ID: 28395525
[TBL] [Abstract][Full Text] [Related]
11. Immuno-oncology trends: preclinical models, biomarkers, and clinical development.
Franklin MR; Platero S; Saini KS; Curigliano G; Anderson S
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35022192
[TBL] [Abstract][Full Text] [Related]
12. Clinical Development and Initial Approval of Novel Immune Checkpoint Inhibitors in Oncology: Insights From a Global Regulatory Perspective.
Serrano P; Hartmann M; Schmitt E; Franco P; Amexis G; Gross J; Mayer-Nicolai C
Clin Pharmacol Ther; 2019 Mar; 105(3):582-597. PubMed ID: 29923615
[TBL] [Abstract][Full Text] [Related]
13. SITC 2018 workshop report: Immuno-Oncology Biomarkers: State of the Art.
Butterfield LH; Disis ML; Fox BA; Kaufman DR; Khleif SN; Wang E;
J Immunother Cancer; 2018 Dec; 6(1):138. PubMed ID: 30514399
[TBL] [Abstract][Full Text] [Related]
14. Cancer Nanomedicine: Lessons for Immuno-Oncology.
Sengupta S
Trends Cancer; 2017 Aug; 3(8):551-560. PubMed ID: 28780932
[TBL] [Abstract][Full Text] [Related]
15. Combination therapies in oncology.
Webster RM
Nat Rev Drug Discov; 2016 Feb; 15(2):81-2. PubMed ID: 26837588
[No Abstract] [Full Text] [Related]
16. Editorial (Thematic Issue: Clinical Advances in Immuno-oncology - Progress Towards Selective Cure).
Liu X; Belani CP
Curr Mol Pharmacol; 2016; 9(3):182. PubMed ID: 26177639
[No Abstract] [Full Text] [Related]
17. Managing Expectations in the Transition to Proof of Concept Studies.
Kieber-Emmons T; Makhoul I; Pennisi A; Siegel ER; Emanuel PD; Monzavi-Karbassi B; Steplewski Z; Beck JT; Hutchins LF
Rev Recent Clin Trials; 2017; 12(2):111-123. PubMed ID: 28325150
[TBL] [Abstract][Full Text] [Related]
18. Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials.
Kohrt HE; Tumeh PC; Benson D; Bhardwaj N; Brody J; Formenti S; Fox BA; Galon J; June CH; Kalos M; Kirsch I; Kleen T; Kroemer G; Lanier L; Levy R; Lyerly HK; Maecker H; Marabelle A; Melenhorst J; Miller J; Melero I; Odunsi K; Palucka K; Peoples G; Ribas A; Robins H; Robinson W; Serafini T; Sondel P; Vivier E; Weber J; Wolchok J; Zitvogel L; Disis ML; Cheever MA;
J Immunother Cancer; 2016; 4():15. PubMed ID: 26981245
[TBL] [Abstract][Full Text] [Related]
19. A Systematic Review of Pediatric Phase I Trials in Oncology: Toxicity and Outcomes in the Era of Targeted Therapies.
Cohen JW; Akshintala S; Kane E; Gnanapragasam H; Widemann BC; Steinberg SM; Shah NN
Oncologist; 2020 Jun; 25(6):532-540. PubMed ID: 31943534
[TBL] [Abstract][Full Text] [Related]
20. A clinical development paradigm for cancer vaccines and related biologics.
Hoos A; Parmiani G; Hege K; Sznol M; Loibner H; Eggermont A; Urba W; Blumenstein B; Sacks N; Keilholz U; Nichol G;
J Immunother; 2007 Jan; 30(1):1-15. PubMed ID: 17198079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
